Alan J. Tackett Institution Verified

Sourced from institutional research profiles (UAMS TRI or ARA).

◆ ARA Academy Federal Grant PI High Impact

IDeA National Resource for Quantitative Proteomics

University of Arkansas for Medical Sciences

faculty

Biochemistry & Molecular Biology, College of Medicine

ajtackett@uams.edu

51 h-index 272 pubs 10,249 cited

Research Areas

Links

ORCID Google Scholar Lab Website Research Group UAMS TRI Profile

Edit your profile

OverviewAI-generated summary

Alan J. Tackett's research focuses on the molecular mechanisms underlying cancer development and potential therapeutic strategies. His work investigates how specific proteins and cellular processes contribute to tumorigenesis, with a particular interest in chromatin regulation and oncogenic signaling pathways. He has published research on the role of phase separation in aberrant chromatin looping and cancer, and has explored the development of targeted therapies, including PROTAC degraders, designed to suppress key oncogenic nodes like c-Myc.

Tackett's investigations extend to the interplay between cancer cells and the immune system, examining approaches to enhance anti-tumor immunity. He also studies the role of endogenous retrotransposons in gene silencing and their connection to cellular processes like those mediated by TNRC18. His research group at the University of Arkansas for Medical Sciences is active in exploring these complex biological questions. Tackett has a substantial publication record with over 270 publications and a citation count exceeding 10,000, reflecting a significant impact in his field. He is recognized as a highly cited researcher and a Federal grant principal investigator.

Metrics

h-index: 51
Publications: 272
Citations: 10,249

Selected Publications

Plasma proteomic profiling reveals distinct protein signatures associated with hepatocellular carcinoma in chronic hepatitis B infection (2026) DOI
Multicellular tumor-stromal interactions recapitulate aspects of therapeutic response and human oncogenic signaling in a 3D disease model for H3K27M-altered DIPG (2025) DOI
BAHCC1 binds H4K20me1 to facilitate the MCM complex loading and DNA replication (2025) DOI
Protective effects of factor XI inhibition by abelacimab in a baboon model of live Staphylococcus aureus sepsis (2025) DOI
EZH2 loss during metabolic stress drives restoration of MHC class I machinery in melanoma (2025) DOI
The phenylalanine-and-glycine repeats of NUP98 oncofusions form condensates that selectively partition transcriptional coactivators (2025) DOI
Staphylococcus aureus Proteins Implicated in the Reduced Virulence of sarA and sarA/agr Mutants in Osteomyelitis (2025) DOI
Dynamic global acetylation remodeling during the yeast heat shock response (2025) DOI
Synthesis and Anti‐Melanoma Activity of Acryloyl Pyridinone Analogues (2023) DOI
TNRC18 engages H3K9me3 to mediate silencing of endogenous retrotransposons (2023) DOI
Resveratrol induces major histocompatibility complex class I antigen presentation in a STING-dependent and independent manner in melanoma (2023) DOI
Increased Response to Immune Checkpoint Inhibitors with Dietary Methionine Restriction in a Colorectal Cancer Model (2023) DOI
Characterization of methionine dependence in melanoma cells (2023) DOI
Oncogenic signaling-mediated regulation of chromatin during tumorigenesis (2023) DOI
Proteomic analysis of transcription factors involved in the alteration of ischemic mouse heart as modulated by MSC exosomes (2023) DOI

ARA Academy 2021 ARA Fellow

Dr. Tackett leads a translational research team examining immunotherapy resistance in cancer treatment, specifically understanding why some patients show limited response to immunotherapies. His work combines research with clinical collaboration among oncologists, surgeons, and pathologists to develop new therapies for metastatic melanoma treatment.

Policy Impact

Advancing cancer immunotherapy research at the UAMS Rockefeller Cancer Institute, attracting federal funding and clinical collaborations that benefit cancer patients statewide.